DK2421513T3 - Hidtil ukendt formulering med indomethacin - Google Patents
Hidtil ukendt formulering med indomethacin Download PDFInfo
- Publication number
- DK2421513T3 DK2421513T3 DK10766521.8T DK10766521T DK2421513T3 DK 2421513 T3 DK2421513 T3 DK 2421513T3 DK 10766521 T DK10766521 T DK 10766521T DK 2421513 T3 DK2421513 T3 DK 2421513T3
- Authority
- DK
- Denmark
- Prior art keywords
- sodium
- milling
- indomethacin
- biologically active
- active material
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Claims (5)
1. Sammensætning, der omfatter partikler af indomethacin, der er dispergeret i mindst to delvist malede formalingsmaterialer, hvor partiklerne har en median partikelstørrelse målt på partikelvolumenbasis, der er mindre end eller lig med en størrelse valgt fra gruppen, der består af 500 nm, 400 nm, 300 nm, 200 nm og 100 nm; hvor de mindst to formalingsmaterialer er natriumlaurylsulfat og lactosemonohydrat.
2. Sammensætning ifølge krav 1, hvor sammensætningen omfatter (vægt/vægt) 8-18 % indomethacin, 0,5-2 % natriumlaurylsulfat, 0-25 % vinsyre og 55-90 % lactosemonohydrat.
3. Sammensætning ifølge krav 2, hvor sammensætningen omfatter (vægt/vægt) 13 % indomethacin, 1 % natriumlaurylsulfat, 21,5 % vinsyre og 64,5 % lactosemonohydrat.
4. Sammensætning ifølge krav 2, hvor sammensætningen omfatter (vægt/vægt) 13 % indomethacin, 1 % natriumlaurylsulfat og 86 % lactosemonohydrat.
5. Farmaceutisk sammensætning, der omfatter sammensætningen ifølge et hvilket som helst af kravene 1 til 4.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17229509P | 2009-04-24 | 2009-04-24 | |
AU2009901745A AU2009901745A0 (en) | 2009-04-24 | A Novel Formulation of Indomethacin | |
PCT/AU2010/000472 WO2010121328A1 (en) | 2009-04-24 | 2010-04-23 | A novel formulation of indomethacin |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2421513T3 true DK2421513T3 (da) | 2018-03-26 |
Family
ID=43010611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10766521.8T DK2421513T3 (da) | 2009-04-24 | 2010-04-23 | Hidtil ukendt formulering med indomethacin |
Country Status (22)
Country | Link |
---|---|
US (8) | US20120135048A1 (da) |
EP (1) | EP2421513B1 (da) |
JP (3) | JP6027890B2 (da) |
KR (3) | KR20140077945A (da) |
CN (2) | CN102438594A (da) |
AP (2) | AP3628A (da) |
AU (1) | AU2010239081C1 (da) |
BR (1) | BRPI1014275B8 (da) |
CA (1) | CA2759125C (da) |
CO (1) | CO6470807A2 (da) |
DK (1) | DK2421513T3 (da) |
EA (1) | EA201171286A1 (da) |
IL (2) | IL215872A (da) |
MA (1) | MA33296B1 (da) |
MX (1) | MX351930B (da) |
MY (1) | MY159208A (da) |
NZ (3) | NZ620879A (da) |
SG (2) | SG175315A1 (da) |
TN (1) | TN2011000544A1 (da) |
UA (1) | UA106231C2 (da) |
WO (1) | WO2010121328A1 (da) |
ZA (1) | ZA201108646B (da) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2960377A1 (en) | 2006-06-30 | 2008-01-03 | Iceutica Pty Ltd | Methods for the preparation of biologically active compounds in nanoparticulate form |
KR101679522B1 (ko) * | 2009-04-24 | 2016-11-24 | 아이슈티카 피티와이 리미티드 | 생물학적 활성 물질의 용해 프로파일 개선방법 |
JP6141013B2 (ja) * | 2009-04-24 | 2017-06-07 | イシューティカ ピーティーワイ リミテッド | 商業的規模での封入ナノ粒子の製造 |
CA2759125C (en) | 2009-04-24 | 2017-08-15 | Iceutica Pty Ltd | A novel formulation of indomethacin |
EP2608878A4 (en) | 2010-08-23 | 2017-11-15 | President and Fellows of Harvard College | Acoustic waves in microfluidics |
CN103249405A (zh) * | 2010-08-23 | 2013-08-14 | 哈佛学院院长等 | 用于药物递送和其他应用的颗粒 |
JP5909796B2 (ja) * | 2012-03-02 | 2016-04-27 | 株式会社サンギ | 難溶性物質の水溶解性改善方法 |
KR102121404B1 (ko) * | 2013-03-15 | 2020-06-11 | 썬 파마 글로벌 에프제트이 | 아비라테론 아세테이트 제제 |
US20150246060A1 (en) | 2013-03-15 | 2015-09-03 | Iceutica Inc. | Abiraterone Acetate Formulation and Methods of Use |
US20150157646A1 (en) | 2013-09-27 | 2015-06-11 | Iceutica Inc. | Abiraterone Steroid Formulation |
US9526734B2 (en) | 2014-06-09 | 2016-12-27 | Iceutica Pty Ltd. | Formulation of meloxicam |
US10258987B2 (en) | 2014-06-26 | 2019-04-16 | President And Fellows Of Harvard College | Fluid infection using acoustic waves |
DK3341116T3 (da) | 2015-08-27 | 2022-05-02 | Harvard College | Sorteringsfremgangsmåde under anvendelse af akustiske bølger |
CN108697700B (zh) | 2016-02-04 | 2021-08-17 | 辛多美制药有限公司 | 氘代多潘立酮组合物和用于治疗病症的方法 |
US11364226B2 (en) | 2017-06-30 | 2022-06-21 | Cinrx Pharma, Llc | Deuterated domperidone compositions, methods, and preparation |
US11197830B2 (en) | 2019-02-27 | 2021-12-14 | Aft Pharmaceuticals Limited | Pharmaceutical composition containing acetaminophen and ibuprofen |
US11701658B2 (en) | 2019-08-09 | 2023-07-18 | President And Fellows Of Harvard College | Systems and methods for microfluidic particle selection, encapsulation, and injection using surface acoustic waves |
TR202017034A2 (tr) * | 2020-10-26 | 2021-09-21 | Hacettepe Ueniversitesi Rektoerluek | Kuru öğütme yöntemi̇ i̇le hazirlanan ve çözünme hizi arttirilmiş selekoksi̇b i̇çeren farmasöti̇k kompozi̇syonlar |
Family Cites Families (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3172546A (en) | 1961-05-19 | 1965-03-09 | Union Carbide Corp | Size reduction of biological substances |
US4133814A (en) | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4200631A (en) * | 1975-12-17 | 1980-04-29 | Richter Gedeon Vegyeszeti Gyar Rt. | Treating mammalian subject sensitive to indomethacin ulcerogenisis |
IT1082518B (it) | 1977-01-25 | 1985-05-21 | Fiat Spa | Specchio a cristallo liquido da impiegare particolarmente come retrovisore per veicoli |
NL175882C (nl) * | 1977-03-28 | Procter & Gamble | Farmaceutisch preparaat, dat een verbinding met ontstekingtegengaande werking bevat. | |
US4380635A (en) | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
DK150008C (da) * | 1981-11-20 | 1987-05-25 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat |
DE3312671A1 (de) | 1983-04-08 | 1984-10-11 | Heinz Finzer KG, 7880 Bad Säckingen | Stanz- und biegewerkzeug-aggregat |
GB8403359D0 (en) * | 1984-02-08 | 1984-03-14 | Erba Farmitalia | Pharmaceutical compositions |
US4851228A (en) * | 1984-06-20 | 1989-07-25 | Merck & Co., Inc. | Multiparticulate controlled porosity osmotic |
IT1227626B (it) | 1988-11-28 | 1991-04-23 | Vectorpharma Int | Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione |
JP2642486B2 (ja) | 1989-08-04 | 1997-08-20 | 田辺製薬株式会社 | 難溶性薬物の超微粒子化法 |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
AU660852B2 (en) | 1992-11-25 | 1995-07-06 | Elan Pharma International Limited | Method of grinding pharmaceutical substances |
US5298262A (en) | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
US5336507A (en) | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
ZA951497B (en) | 1994-03-02 | 1996-08-23 | Lilly Co Eli | Orally administerable pharmaceutical formulations |
US5478705A (en) | 1994-05-25 | 1995-12-26 | Eastman Kodak Company | Milling a compound useful in imaging elements using polymeric milling media |
US5500331A (en) | 1994-05-25 | 1996-03-19 | Eastman Kodak Company | Comminution with small particle milling media |
US5631369A (en) | 1994-08-31 | 1997-05-20 | Eli Lilly And Company | Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceutical agents |
US5534270A (en) | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
US5591456A (en) | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
TW487582B (en) | 1995-08-11 | 2002-05-21 | Nissan Chemical Ind Ltd | Method for converting sparingly water-soluble medical substance to amorphous state |
SE9600070D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
US6458811B1 (en) | 1996-03-26 | 2002-10-01 | Eli Lilly And Company | Benzothiophenes formulations containing same and methods |
US6713494B1 (en) | 1996-08-28 | 2004-03-30 | Eli Lilly And Company | Amorphous benzothiophenes, methods of preparation and methods of use |
WO1998035666A1 (en) | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Formulations of nanoparticle naproxen tablets |
JP4117811B2 (ja) * | 1997-04-22 | 2008-07-16 | 日本化薬株式会社 | フルタミド製剤及びその製法 |
BR9812018A (pt) * | 1997-08-27 | 2000-09-26 | Hexal Ag | Composições farmacêuticas de meloxicam com solubilidade e biodisponibilidade melhoradas |
JPH11130698A (ja) * | 1997-10-31 | 1999-05-18 | Freunt Ind Co Ltd | アルギン酸多価金属塩球状微粒子集合体、該球状微粒子集合体に難溶性薬剤を担持した放出制御製剤及びそれらの製造方法 |
US6165506A (en) | 1998-09-04 | 2000-12-26 | Elan Pharma International Ltd. | Solid dose form of nanoparticulate naproxen |
JP2000095674A (ja) | 1998-09-22 | 2000-04-04 | Sato Pharmaceutical Co Ltd | 口腔内崩壊時間短縮化錠剤の製造方法及び装置 |
US20040013613A1 (en) | 2001-05-18 | 2004-01-22 | Jain Rajeev A | Rapidly disintegrating solid oral dosage form |
US8236352B2 (en) | 1998-10-01 | 2012-08-07 | Alkermes Pharma Ireland Limited | Glipizide compositions |
US8293277B2 (en) | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
US6428814B1 (en) | 1999-10-08 | 2002-08-06 | Elan Pharma International Ltd. | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
US7521068B2 (en) | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
EP1066825A1 (en) | 1999-06-17 | 2001-01-10 | The Procter & Gamble Company | An anti-microbial body care product |
DE19932157A1 (de) | 1999-07-13 | 2001-01-18 | Pharmasol Gmbh | Verfahren zur schonenden Herstellung von hochfeinen Mikropartikeln und Nanopartikeln |
US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
WO2002000197A1 (en) | 2000-06-27 | 2002-01-03 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
JP4969761B2 (ja) | 2000-08-31 | 2012-07-04 | オバン・エナジー・リミテッド | 所望粒度を持つ固体基材の小粒子および第一材料の小粒状物を含む相乗作用性混合物を製造する方法 |
US7276249B2 (en) | 2002-05-24 | 2007-10-02 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
DE60137362D1 (de) | 2000-11-20 | 2009-02-26 | Elan Pharma Int Ltd | Nanopartikel bestehend aus einem arzneistoff und copolymeren von vinyl pyrrolidon und vinyl acetat als oberflächenstabilisatoren |
PT1920763E (pt) | 2000-11-30 | 2014-06-25 | Vectura Ltd | Composições farmacêuticas para inalação |
WO2002045684A2 (en) | 2000-12-06 | 2002-06-13 | Pharmacia Corporation | Rapidly dispersing pharmaceutical composition comprising effervescent agents |
FI20010115A0 (fi) | 2001-01-18 | 2001-01-18 | Orion Corp | Menetelmä nanopartikkelien valmistamiseksi |
DE60203506T2 (de) | 2001-06-22 | 2006-02-16 | Marie Lindner | Screening-verfahren mit hohem durchsatz (hts) unter verwendung von labormühlen oder microfluidics |
JP2003066613A (ja) | 2001-08-22 | 2003-03-05 | Columbia Music Entertainment Inc | スタンパの製造方法 |
EP1443912B1 (en) | 2001-10-12 | 2007-08-29 | Elan Pharma International Limited | Compositions having a combination of immediate release and controlled release characteristics |
US7714006B1 (en) | 2001-12-03 | 2010-05-11 | King Pharmaceuticals Research & Development, Inc. | Methods of modifying the bioavailability of metaxalone |
US6407128B1 (en) | 2001-12-03 | 2002-06-18 | Elan Pharmaceuticals, Inc. | Method for increasing the bioavailability of metaxalone |
US7101576B2 (en) | 2002-04-12 | 2006-09-05 | Elan Pharma International Limited | Nanoparticulate megestrol formulations |
US6825161B2 (en) | 2002-04-26 | 2004-11-30 | Salvona Llc | Multi component controlled delivery system for soap bars |
AU2003276688A1 (en) | 2002-09-02 | 2004-03-19 | Sun Pharmaceutical Industries Limited | Pharmaceutical composition of metaxalone with enhanced oral bioavailability |
JP2004099442A (ja) * | 2002-09-04 | 2004-04-02 | Nisshin Pharma Inc | 難溶性薬物含有製剤およびその製造方法 |
AU2003266940B2 (en) | 2002-09-30 | 2007-02-08 | A/S Gea Farmaceutisk Fabrik | Novel raloxifene acid addition salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these |
AU2003297151A1 (en) | 2002-12-17 | 2004-07-22 | Elan Pharma International Ltd. | Milling microgram quantities of nanoparticulate candidate compounds |
US20040121003A1 (en) | 2002-12-19 | 2004-06-24 | Acusphere, Inc. | Methods for making pharmaceutical formulations comprising deagglomerated microparticles |
WO2004066981A1 (en) | 2003-01-29 | 2004-08-12 | Sun Pharmaceutical Industries Limited | Oral controlled release pharmaceutical composition containing metaxalone as active agent |
US8512727B2 (en) | 2003-03-03 | 2013-08-20 | Alkermes Pharma Ireland Limited | Nanoparticulate meloxicam formulations |
US7749533B2 (en) * | 2003-05-07 | 2010-07-06 | Akina, Inc. | Highly plastic granules for making fast melting tablets |
DE60309356T2 (de) * | 2003-06-27 | 2007-08-30 | Bioprogress S.P.A. | Zusammensetzung, durch zusammen vermahlen eines wirkstoffes mit einem n-vinyl-2-pyrrolidon/vinylacetatkopolymers erhältlich |
US20050042177A1 (en) | 2003-07-23 | 2005-02-24 | Elan Pharma International Ltd. | Novel compositions of sildenafil free base |
WO2005016310A1 (en) | 2003-08-08 | 2005-02-24 | Elan Pharma International Ltd. | Novel metaxalone compositions |
WO2005020933A2 (en) | 2003-09-02 | 2005-03-10 | University Of South Florida | Nanoparticles for drug-delivery |
BRPI0414982A (pt) | 2003-10-01 | 2006-11-21 | Debio Rech Pharma Sa | dispositivo e método para produção de partìculas |
CA2544627A1 (en) | 2003-11-05 | 2005-05-19 | Elan Pharma International Ltd. | Nanoparticulate compositions having a peptide as a surface stabilizer |
ES2430849T3 (es) | 2004-03-08 | 2013-11-22 | Spiridon Spireas | Formas de dosificación sólidas biodisponibles de metaxalona |
CN101005828B (zh) | 2004-06-17 | 2012-01-11 | 维尔恩公司 | 用于经粘膜递送活性成分的包含粘膜粘附蛋白和所述活性物质的组合物 |
WO2006009419A1 (es) | 2004-07-19 | 2006-01-26 | Luis Cordova Boone | Neumáticos con doble banda de rodamiento |
KR20060024927A (ko) | 2004-09-15 | 2006-03-20 | 씨제이 주식회사 | 기계적 분쇄법에 의한 미크론 사이즈 인삼 분말의제조방법 |
WO2006041843A2 (en) | 2004-10-04 | 2006-04-20 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical dosage form comprising meloxicam |
AU2005297923B2 (en) * | 2004-10-25 | 2010-12-23 | Japan Tobacco Inc. | Solid medicinal preparation improved in solubility and stability and process for producing the same |
EP1817008B1 (en) | 2004-11-09 | 2020-04-01 | Board of Regents, The University of Texas System | Stabilized hme composition with small drug particles |
UA89513C2 (uk) | 2004-12-03 | 2010-02-10 | Элан Фарма Интернешнл Лтд. | Стабільна композиція з наночастинок ралоксифену гідрохлориду |
JP6091041B2 (ja) | 2004-12-31 | 2017-03-08 | イシューティカ ピーティーワイ リミテッド | ナノ粒子組成物及びその合成方法 |
EA200702444A1 (ru) | 2005-05-10 | 2008-04-28 | Элан Фарма Интернэшнл Лимитед | Композиции с наночастицами клопидогреля |
JO3352B1 (ar) | 2005-06-17 | 2019-03-13 | Apr Applied Pharma Res Sa | صيغ دايكلوفيناك وطرق استخدامه |
US20080292584A1 (en) | 2005-10-14 | 2008-11-27 | Mutual Pharmaceutical Company, Inc. | Metaxalone products, method of manufacture, and method of use |
WO2007070851A2 (en) * | 2005-12-15 | 2007-06-21 | Acusphere, Inc. | Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration |
DK1973527T3 (da) | 2005-12-15 | 2010-02-01 | Acusphere Inc | Fremgangsmåder til fremstilling af partikelbaserede farmaceutiske formulationer til parenteral indgivelse |
EP1978933A2 (en) | 2005-12-15 | 2008-10-15 | Acusphere, Inc. | Processes for making particle-based pharmaceutical formulations for oral administration |
WO2007074477A2 (en) | 2005-12-29 | 2007-07-05 | Dabur Pharma Limited | Metaxalone polymorphs |
US8420122B2 (en) | 2006-04-28 | 2013-04-16 | Merck Sharp & Dohme Corp. | Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same |
EP2012763B1 (en) | 2006-04-28 | 2011-03-23 | Grünenthal GmbH | Pharmaceutical combination comprising 3- (3-dimethylamin0-1-ethyl-2-methyl-pr0pyl) -phenol and an nsaid |
KR20090023729A (ko) | 2006-06-23 | 2009-03-05 | 엘란 파마 인터내셔널 리미티드 | 나노입자형 멜록시캄 및 조절 방출형 하이드로코돈을 포함하는 조성물 |
CA2960377A1 (en) * | 2006-06-30 | 2008-01-03 | Iceutica Pty Ltd | Methods for the preparation of biologically active compounds in nanoparticulate form |
NZ599069A (en) | 2006-06-30 | 2013-10-25 | Iceutica Pty Ltd | Methods for the Preparation of Biologically Active Compounds in Nanoparticulate Form |
CN100386312C (zh) | 2006-07-18 | 2008-05-07 | 上海世景国际贸易有限公司 | 2,4-二氨基苯磺酸及其盐的合成方法 |
WO2008013416A1 (en) | 2006-07-27 | 2008-01-31 | Amorepacific Corporation | Process for preparing powder comprising nanoparticles of sparingly soluble drug |
GB0625322D0 (en) * | 2006-12-19 | 2007-01-24 | Pharmakodex Ltd | Pharmaceutical compositions |
PE20081891A1 (es) | 2007-03-22 | 2008-12-27 | Opko Health Inc | Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas |
TWI405590B (zh) * | 2007-04-06 | 2013-08-21 | Activus Pharma Co Ltd | 微粉碎化有機化合物粒子之製法 |
AR067997A1 (es) | 2007-08-24 | 2009-10-28 | Novartis Ag | Compuestos organicos |
US8568696B2 (en) | 2008-08-06 | 2013-10-29 | Indiana Nanotech Llc | Grinding method for the manipulation or preservation of calcium phosphate hybrid properties |
AU2010239085C1 (en) | 2009-04-24 | 2014-10-16 | Iceutica Pty Ltd | A novel formulation of naproxen |
JP6141013B2 (ja) | 2009-04-24 | 2017-06-07 | イシューティカ ピーティーワイ リミテッド | 商業的規模での封入ナノ粒子の製造 |
MY161430A (en) | 2009-04-24 | 2017-04-14 | Iceutica Pty Ltd | A method for producing a composition of meloxicam |
SG10201401712QA (en) | 2009-04-24 | 2014-08-28 | Iceutica Pty Ltd | Method for the production of commercial nanoparticle and microparticle powders |
MY168079A (en) | 2009-04-24 | 2018-10-11 | Iceutica Pty Ltd | A novel formulation of diclofenac |
EA201171279A1 (ru) | 2009-04-24 | 2012-05-30 | Айсьютика Пти Лтд. | Производство инкапсулированных наночастиц с высокой объемной долей |
CA2759125C (en) * | 2009-04-24 | 2017-08-15 | Iceutica Pty Ltd | A novel formulation of indomethacin |
KR101679522B1 (ko) | 2009-04-24 | 2016-11-24 | 아이슈티카 피티와이 리미티드 | 생물학적 활성 물질의 용해 프로파일 개선방법 |
AU2010239082B2 (en) | 2009-04-24 | 2014-10-16 | Iceutica Pty Ltd | A novel formulation of metaxalone |
JP2011005735A (ja) | 2009-06-25 | 2011-01-13 | Olympus Corp | 画像記録装置及び画像記録装置の初期化制御方法 |
-
2010
- 2010-04-23 CA CA2759125A patent/CA2759125C/en active Active
- 2010-04-23 MX MX2011011226A patent/MX351930B/es active IP Right Grant
- 2010-04-23 JP JP2012506290A patent/JP6027890B2/ja not_active Expired - Fee Related
- 2010-04-23 NZ NZ620879A patent/NZ620879A/en not_active IP Right Cessation
- 2010-04-23 CN CN201080018017XA patent/CN102438594A/zh active Pending
- 2010-04-23 US US13/266,125 patent/US20120135048A1/en not_active Abandoned
- 2010-04-23 NZ NZ710384A patent/NZ710384A/en not_active IP Right Cessation
- 2010-04-23 KR KR1020147011503A patent/KR20140077945A/ko active Search and Examination
- 2010-04-23 NZ NZ595986A patent/NZ595986A/en not_active IP Right Cessation
- 2010-04-23 WO PCT/AU2010/000472 patent/WO2010121328A1/en active Application Filing
- 2010-04-23 AP AP2011005992A patent/AP3628A/xx active
- 2010-04-23 EP EP10766521.8A patent/EP2421513B1/en active Active
- 2010-04-23 SG SG2011077468A patent/SG175315A1/en unknown
- 2010-04-23 KR KR1020157005724A patent/KR101743847B1/ko active IP Right Grant
- 2010-04-23 UA UAA201113759A patent/UA106231C2/uk unknown
- 2010-04-23 SG SG10201401695VA patent/SG10201401695VA/en unknown
- 2010-04-23 AP AP2015008955A patent/AP2015008955A0/xx unknown
- 2010-04-23 BR BRPI1014275A patent/BRPI1014275B8/pt not_active IP Right Cessation
- 2010-04-23 AU AU2010239081A patent/AU2010239081C1/en not_active Ceased
- 2010-04-23 MY MYPI2011005116A patent/MY159208A/en unknown
- 2010-04-23 MA MA34382A patent/MA33296B1/fr unknown
- 2010-04-23 KR KR1020117027889A patent/KR20120101285A/ko active Application Filing
- 2010-04-23 EA EA201171286A patent/EA201171286A1/ru unknown
- 2010-04-23 DK DK10766521.8T patent/DK2421513T3/da active
- 2010-04-23 CN CN201410140157.4A patent/CN103932988A/zh active Pending
-
2011
- 2011-10-23 IL IL215872A patent/IL215872A/en active IP Right Grant
- 2011-10-24 TN TNP2011000544A patent/TN2011000544A1/en unknown
- 2011-11-23 CO CO11160588A patent/CO6470807A2/es not_active Application Discontinuation
- 2011-11-24 ZA ZA2011/08646A patent/ZA201108646B/en unknown
-
2013
- 2013-02-25 US US13/776,536 patent/US8734847B2/en active Active
-
2014
- 2014-01-06 US US14/148,635 patent/US9095496B2/en active Active
- 2014-05-20 US US14/282,915 patent/US8992982B2/en active Active
- 2014-05-22 US US14/284,981 patent/US9089471B2/en active Active
- 2014-11-10 JP JP2014227872A patent/JP6043329B2/ja not_active Expired - Fee Related
-
2015
- 2015-07-27 US US14/810,240 patent/US9522135B2/en active Active
-
2016
- 2016-08-01 IL IL247034A patent/IL247034A/en active IP Right Grant
- 2016-09-12 JP JP2016177675A patent/JP6239709B2/ja not_active Expired - Fee Related
- 2016-12-19 US US15/384,174 patent/US9849111B2/en active Active
-
2017
- 2017-12-22 US US15/852,596 patent/US10172828B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10172828B2 (en) | Formulation of indomethacin | |
US20180296514A1 (en) | Novel formulation of diclofenac | |
AU2016200397B2 (en) | A Novel Formulation of Indomethacin | |
AU2014202776B2 (en) | A Novel Formulation of Indomethacin | |
AU2014208310C1 (en) | A Novel Formulation of Diclofenac |